Longer-term (96-week) efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in women

被引：0
|
作者：
Kityo, C. [1 ]
Hagins, D. [2 ]
Koenig, E. [3 ]
Avihingsanon, A. [4 ]
Chetchotisakd, P. [5 ]
Supparatpinyo, K. [6 ]
Gankina, N. [7 ]
Pokrovsky, V. [8 ]
Voronin, E. [9 ]
Stephens, J. L. [10 ]
DeJesus, E. [11 ]
Wang, H. [12 ]
Acosta, R. [12 ]
Brainard, D. [12 ]
Martin, H. [12 ]
Makadzange, T. A. [12 ]
机构：
[1] Joint Clin Res Ctr, Kampala, Uganda
[2] Chatham Care Ctr, Georgia Dept Publ Hlth, Savannah, GA USA
[3] Inst Dominicano Estudios Virol IDEV, Dr Pineyro 211, Santo Domingo, Dominican Rep
[4] Thai Red Cross AIDS Res Ctr, HIV Netherlands Australia Thailand Res Collaborat, Bangkok, Thailand
[5] Srinagarind Hosp, Khon Kaen, Thailand
[6] Chiang Mai Univ, Chiang Mai, Thailand
[7] Krasnoyarsk Terr Ctr Prevent & Control AIDS & Inf, Krasnoyarsk, Russia
[8] Ctr Prevent & Control AIDS, Moscow, Russia
[9] Republican Clin Infect Hosp, Minist Hlth Russian Federat, Fed State Inst, St Petersburg, Russia
[10] Mercer Univ, Sch Med, Macon, GA 31207 USA
[11] Orlando Immunol Ctr, Orlando, FL USA
[12] Gilead Sci, Foster City, CA USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
MOAB0106
引用
收藏
页码：4 / 4
页数：1
相关论文
共 50 条
  • [31] Real-world experience using bictegravir/emtricitabine/tenofovir-alafenamide (B/F/TAF) in a Scottish HIV cohort
    Proud, E.
    Murphy, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 46 - 47
  • [32] Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trial
    Maggiolo, F.
    Rizzardini, G.
    Molina, J. M.
    Pulido, F.
    DeWit, S.
    Vandekerckhove, L.
    Berenguer, J.
    D'Antoni, M.
    Blair, C.
    Chuck, S.
    Piontkowsky, D.
    Martin, H.
    McNicholl, I.
    Payne, B.
    Gallant, J.
    HIV MEDICINE, 2020, 21 : 17 - 17
  • [33] Modelling the long-term clinical outcomes of the novel single-tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in the UK
    Hearmon, N.
    Matin, N.
    Painter, C.
    Robinson, C.
    Eddowes, L.
    Kearns, S.
    Jandu, S.
    Wild, L.
    HIV MEDICINE, 2019, 20 : 21 - 21
  • [34] The safety and efficacy of the use of Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) with boosted darunavir in clinical practice
    Tyler, Stephanie
    Collins, Nadine
    Barchi, Will
    Kulasegaram, Ranjababu
    HIV MEDICINE, 2022, 23 : 32 - 32
  • [35] Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged>65 or older: week 48 results from a phase 3b, open-label trial
    Maggiolo, F.
    Rizzardini, G.
    Molina, J-M
    Pulido, F.
    De Wit, S.
    Vandekerckhove, L.
    Berenguer, J.
    D'Antoni, M.
    Blair, C.
    Chuck, S.
    Piontkowsky, D.
    Martin, H.
    McNicholl, I.
    Haubrich, R.
    Gallant, J.
    HIV MEDICINE, 2019, 20 : 138 - 138
  • [36] Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) single-tablet regimen in HIV-1-infected children (6 to <12 years)
    Cotton, M.
    Liberty, A.
    Rodriguez, C. A.
    Chokephaibulkit, K.
    Kosalaraksa, P.
    Hellstrom, E.
    Natukunda, E.
    Wong, P.
    Majeed, S. R.
    Quirk, E.
    Graham, H.
    Pikora, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 38 - 39
  • [37] ECONOMIC IMPACT OF RAPID TREATMENT INITIATION OF HIV WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (B/F/TAF) FROM A CANADIAN HEALTHCARE PERSPECTIVE
    Guinan, K.
    Mathurin, K.
    Lachaine, J.
    VALUE IN HEALTH, 2023, 26 (06) : S184 - S185
  • [38] 96-WEEK EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) SWITCH VS. CONTINUED TDF TREATMENT AMONG VIROLOGICALLY-SUPPRESSED HEPATITIS B PATIENTS OF ASIAN ETHNICITY
    Ahn, Sang Hoon
    Kao, Jia-Horng
    Lampertico, Pietro
    Ramji, Alnoor
    Fung, Scott
    Chuang, Wan-Long
    Kim, Yoon Jun
    Chen, Chi-Yi
    Tam, Edward
    Bae, Ho
    Ma, Xiaoli
    Lee, June Sung
    Chan, Carol Yee Kwan
    Yee, Leland J.
    Sethi, Shalini
    Flaherty, John
    Zhao, Yang
    Gaggar, Anuj
    Hann, Hie Won
    Lim, Young-Suk
    Chan, Henry Lik Yuen
    GUT, 2021, 70 : A77 - A78
  • [39] Restarting bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF) after virologic rebound: A pooled analysis of studies in people with HIV-1
    Pozniak, A.
    Orkin, C.
    Maggiolo, F.
    Yazdanpanah, Y.
    Baumgarten, A.
    Mounzer, K.
    D'Antoni, M. L.
    Huang, H.
    Liu, H.
    Andreatta, K.
    VanderVeen, L.
    Callebaut, C.
    Hindman, J. T.
    Martin, H.
    Arribas, J. R.
    HIV MEDICINE, 2023, 24 : 195 - 196
  • [40] Intermittent bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) maintains viral suppression in real life in controlled HIV-infected patients
    Sellem, B.
    Abdi, B.
    Peytavin, G.
    Tubiana, R.
    Valantin, M. -A.
    Seang, S.
    Schneider, L.
    Faycal, A.
    Soulie, C.
    Marcelin, A. -G.
    Katlama, C.
    Pourcher, V.
    Palich, R.
    HIV MEDICINE, 2021, 22 : 90 - 91
12345